deferiprone (Ferriprox)

^[1]^[2]

Indications

transfusion-related iron overload in patients with thalassemia who do not respond to prior chelation therapy (FDA-approved 10/2011)

brain iron chelation with deferiprone associated with worsening of parkinsonism symptoms & adverse events in early Parkinson's disease^[2]

↑ FDA NEWS RELEASE: Oct. 14, 2011 FDA approves Ferriprox to treat patients with excess iron in the body http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
↑ ^2.0 ^2.1 George J Brain Iron Chelation Linked With Worse Outcomes in Early Parkinson's. Findings raise caution about iron chelation in neurodegenerative disorders. MedPage Today December 2, 2022 https://www.medpagetoday.com/neurology/parkinsonsdisease/102035
Devos D, Labreuche J, Rascol O et al Trial of Deferiprone in Parkinson's Disease. N Engl J Med 2022; 387:2045-2055. Dec 1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36449420 https://www.nejm.org/doi/full/10.1056/NEJMoa2209254